Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | STK17B | O94768 | 1/20 | 0.42 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.42 |
| ▸ | LATS1 | O95835 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3092617 | 0.86 | IDO1 (0.45) | IDO1LMNAMEN1KMT2ATSHR | |
| SCHEMBL3089405 | 0.84 | IDO1 (0.41) | IDO1LMNAMEN1KMT2ATSHR | |
| SCHEMBL6240507 | 0.84 | IDO1 (0.43) | IDO1LMNAMEN1KMT2ATSHR | |
| SCHEMBL13095166 | 0.83 | IDO1 (0.41) | IDO1LMNAMEN1KMT2ATSHR | |
| SCHEMBL27386752 | 0.81 | CYP3A4 (0.51) | IDO1LMNAMEN1KMT2ATSHR | |
| SCHEMBL7866002 | 0.81 | IDO1 (0.47) | IDO1LMNAMEN1KMT2ATSHR | |
| SCHEMBL6235868 | 0.81 | IDO1 (0.41) | IDO1LMNAMEN1KMT2ATSHR | |
| SCHEMBL7867220 | 0.80 | LATS1 (0.45) | IDO1LMNAMEN1KMT2ATSHR | |
| SCHEMBL7866101 | 0.79 | HPGD (0.46) | IDO1LMNAMEN1KMT2ATSHR | |
| SCHEMBL27370470 | 0.77 | LMNA (0.44) | IDO1LMNAMEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445476-B2 | Carbacephem β-lactam antibiotics | ACHAOGEN, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110224186-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20100267686-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| CN-101835777-A | Carbacephem beta-lactam antibiotics | ACHAOGEN INC | 2010-09-15 | — | — | CN | disclosed |
| EP-2205600-A1 | CARBACEPHEM ß -LACTAM ANTIBIOTICS | Achaogen, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| WO-2010030810-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010030811-A2 | CARBACEPHEM β-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| EP-2161268-A1 | Carbacephem beta-lactam compounds for the treatment of bacterial infections | Trine Pharmaceuticals, Inc. (US) | 2010-03-10 | — | — | EP | disclosed |
| EP-1618106-B1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | TRINE PHARMACEUTICALS INC (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2009055696-A1 | CARBACEPHEM β-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| EP-0874854-B1 | CEPHALOSPORIN ANTIBIOTICS | MICROCIDE PHARMACEUTICALS INC (US) | 2001-12-12 | — | — | EP | disclosed |
| EP-1059293-A1 | Novel amino chlorothiazole compounds | Microcide Pharmaceuticals, Inc. (US) | 2000-12-13 | — | — | EP | disclosed |
| US-6087355-A | A THERAPEUTIC BACTERICIDE COMPOSITION FOR TREATING A METHICILLIN-RESISTANT, VANCOMYCIN-RESISTANT, OR AMPICILLIN-RESISTANT BACTERIAL INFECTION | MICROCIDE PHARMACEUTICALS, INC. (US) | 2000-07-11 | — | — | US | disclosed |
| US-6066630-A | ACTIVE AGAINST ANTIBIOTIC RESISTANT BACTERIA | MICROCIDE PHARMACEUTICALS, INC. (US) | 2000-05-23 | — | — | US | disclosed |
| US-6057312-A | TREATING ANTIBIOTIC RESISTANT BACTERIAL INFECTIONS | MICROCIDE PHARMACEUTICALS, INC. (US) | 2000-05-02 | — | — | US | disclosed |
| US-6030965-A | WIDE SPECTRAM ANTIBIOTICS | MICROCIDE PHARMACEUTICALS, INC. (US) | 2000-02-29 | — | — | US | disclosed |
| US-6025352-A | Cephalosporin antibiotics | MICROCIDE PHARMACEUTICALS, INC. (US) | 2000-02-15 | — | — | US | disclosed |
| US-5859256-A | CHLORINATION; USEFUL AS ANTIBACTERIAL AGENTS AND IN TREATING DISEASES CAUSED BY ORGANISMS WHICH ARE RESISTANT TO BETA-LACTAM ANTIBIOTICS | MICROCIDE PHARMACEUTICALS, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0874854-A2 | CEPHALOSPORIN ANTIBIOTICS | Microcide Pharmaceuticals, Inc. (US) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997013772-A2 | CEPHALOSPORIN ANTIBIOTICS | MICROCIDE PHARMACEUTICALS, INC. (US) | 1997-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224186-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | MGAM, MGAM2, B2M | IDO1 2104/4885LMNA 3775/4885MEN1 2327/4885 |
| US-20100267686-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | MGAM, MGAM2, B2M | IDO1 2341/4885LMNA 4295/4885MEN1 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.